PARP inhibitors in prostate cancer: time to narrow patient selection?

Mark C. Markowski, Emmanuel S. Antonarakis

Research output: Contribution to journalEditorialpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)523-526
Number of pages4
JournalExpert Review of Anticancer Therapy
StatePublished - 2020


  • PARP inhibitors
  • metastatic castration-resistant prostate cancer
  • niraparib
  • olaparib
  • prostate cancer
  • rucaparib
  • talazoparib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this